Wellgistics Health (NASDAQ:MEDS) Stock Rating Cut to Strong Sell at Wall Street Zen

Wall Street Zen downgraded shares of Wellgistics Health (NASDAQ:MEDS) to a strong sell rating in a research report released on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Wellgistics Health in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Wellgistics Health Stock Down 12.9%

NASDAQ:MEDS opened at $2.96 on Friday. Wellgistics Health has a 52 week low of $0.82 and a 52 week high of $73.00. The stock’s 50-day moving average price is $2.79 and its 200-day moving average price is $3.88. The stock has a market capitalization of $9.47 million, a PE ratio of -0.06 and a beta of -3.51.

Wellgistics Health (NASDAQ:MEDS) last released its quarterly earnings results on Monday, August 17th. The company reported ($7.13) earnings per share for the quarter. The company had revenue of $1.78 million during the quarter.

About Wellgistics Health

Wellgistics Health, Inc is a healthcare technology and pharmaceutical distribution company focused on improving access to prescription medications. The company connects pharmaceutical manufacturers, wholesalers, pharmacies, healthcare providers and patients through technology-enabled services designed to support the movement and dispensing of medications.

Its business includes pharmaceutical distribution and related supply-chain solutions, with an emphasis on helping pharmacies and healthcare organizations source and manage prescription products.